Background Obesity may negatively affect survival in breast cancer (BC), but studies are conflicting, and associations may vary by tumor subtypes and race/ethnicity groups. Methods In a retrospective review, we identified 273 women with invasive BC administered Adriamycin/Taxane-based neoadjuvant chemotherapy from 2004 to 2016 with body mass index (BMI) data at diagnosis. Obesity was defined as BMI C30. Associations between obesity and event-free survival (EFS), using STEEP events, and overall survival (OS), using all-cause mortality, were assessed overall and stratified by tumor subtype [[Hormone Receptor Positive (HR?)/HER2-, HER2?, and TripleNegative Breast Cancer (TNBC])] in our diverse population. Results Median follow-up was 32.6 months (range 5.7-137.8 months). Overall, obesity was associated with worse EFS (HR 1.71, 95% CI 1.03-2.84, p = 0.04) and a trend towards worse OS (p = 0.13). In HR?/HER2-disease (n = 135), there was an interaction between obesity and hormonal therapy with respect to OS but not EFS. In those receiving tamoxifen (n = 33), obesity was associated with worse OS (HR 9.27, 95% CI 0.96-89.3, p = 0.05). In those receiving an aromatase inhibitor (n = 89), there was no association between obesity and OS. In TNBC (n = 44), obesity was associated with worse EFS (HR 2.62, 95% CI 1.03-6.66, p = 0.04) and a trend towards worse OS (p = 0.06). In HER2? disease (n = 94), obesity was associated with a trend towards worse EFS (HR 3.37, 95% CI 0.97-11.72, p = 0.06) but not OS. Race/ethnicity was not associated with survival in any subtype, and there were no interactions with obesity on survival. Conclusions Obesity may negatively impact survival, with differences among tumor subtypes.
Introduction
Obesity is associated with various poor health outcomes and is implicated in 5-10% of US health care spending [1, 2] . Epidemiologic studies have suggested that obesity confers increased risk of developing breast cancer (BC) [3, 4] and is independently associated with poor clinical outcomes in BC [4] [5] [6] [7] . Proposed mechanisms range from difficulties with screening and chemotherapy dosing to underlying genetic/molecular differences [8] .
The effect of obesity on BC outcomes, however, is less clear as the impact of obesity may vary by tumor subtype, menopausal status, and hormone therapy class [9, 10] . Some studies have shown the association to be strongest in those with hormone receptor-positive (HR?) disease [11, 12] , while others have suggested an association in triple-negative breast cancer (TNBC) and HER2-positive (HER2?) tumors as well [13] [14] [15] [16] .
Rates of obesity also vary among different race/ethnicity groups, with Blacks and Hispanics more likely to be obese as compared to Non-Hispanic Whites [17] . Although some have hypothesized that obesity may influence survival differently in various racial/ethnic groups, studies are small and conflicting [18] , and health disparities exist among minorities with respect to cancer outcomes which may confound the impact of obesity [19] . In Asian women, obesity may predict worse survival, [14, 18] but in studies of Black and Hispanic women, no differences have been reported in the association between obesity and clinical outcomes as compared to Non-Hispanic White women [20, 21] . Differences may exist in certain subtypes, such as HR? disease [18, 20, 21] , or using different markers of obesity, such as waist circumference and waist-to-hip ratio [22] .
Additionally, few have investigated the impact of obesity in the neoadjuvant setting on event-free (EFS) and overall survival (OS). Most studies have focused on pathologic complete response (pCR), a surrogate marker for survival in the neoadjuvant setting [23] , and some report that obese patients have lower rates of pCR with a suggestion of worse survival [24] . However, others have shown no differences in pCR or survival between different body mass index (BMI) groups [21, 25] , and many of the studies are limited to homogenous, clinical trial populations. The impact of obesity on BC survival in the neoadjuvant setting, and in particular the role of tumor subtype and race/ethnicity, is still unknown.
Our study seeks to examine the role of baseline obesity, as measured by BMI, on EFS and OS in women with invasive BC receiving neoadjuvant chemotherapy (NAC) and to explore if tumor subtype influences these associations in our ethnically diverse population.
Methods

Patient Population
We performed a retrospective review of women with invasive breast cancer seeking care at Columbia University Medical Center (CUMC) between January 2004 and February 2016 administered Adriamycin(A)/Taxane(T)-based NAC. Clinicopathologic data were abstracted from medical records by four independent researchers. All data were double-verified, and discrepancies were resolved by oncologists EC and KK. Of the 342 unique women identified, 317 women had undergone surgery at the time of this analysis. We excluded 10 women who were metastatic at diagnosis, five women who received non-A/T-based NAC (all received CMF), 1 who was pregnant and ultimately did not receive NAC, and three women with unknown NAC regimens, resulting in a final cohort of 298 women. Of these, 273 women had complete data on BMI at diagnosis and were included in this analysis. All research was conducted in accordance with CUMC IRB-approved protocol (IRB # AAAJ8512).
Clinical and Pathologic Variables
BMI was calculated from height and weight documented at the clinic visit closest to pathologic diagnosis. BMI was defined as weight in kilograms divided by height in m 2 . BMI was also collected at the most recent clinic visit to assess change over time. Obesity was classified according to World Health Organization guidelines, and obesity was defined as BMI C 30 [26] . BSA (body surface area) in meters squared (m 2 ) was calculated using the DuBois formula (BSA = 0.00718 9 Height(cm) 0.725 9 Weight(kg) 0.425 ), and a BSA C 2.2 was defined as high [27] . A diagnosis of diabetes was inferred from physician notes at breast cancer diagnosis.
Age was defined in years at diagnosis and was stratified into \ 50 years of age and C 50 years of age. Race/ethnicity was categorized as Non-Hispanic White, Non-Hispanic Black, Hispanic, and Asian/Other based on selfreport or physician notes. Tumor size was defined as the largest dimension on any imaging modality prior to any treatment and was stratified at 0-2, [ 2-5, and [ 5 cm. Grade was defined as the highest grade seen on any biopsy and was defined as low/intermediate grade (grade 1 and 2) and high grade (grade 3). Estrogen receptor (ER) and progesterone receptor (PR) positivity were defined as 1% or greater expression on any biopsy in accordance with the American Society of Clinical Oncology/College of American Pathologist (ASCO/CAP) guidelines from 2010 [28] . Tumors were considered HER2 positive if they were 3? by immunohistochemistry (IHC), demonstrated gene amplification with a ratio of Her-2/CEP17 C 2.2 by in situ hybridization, or had HER2 average copies/cell C 6 on either the core biopsy or surgical pathology specimen [29] . Based on prior studies, subtype groups were defined as (a) HR?(ER and/or PR positive) and HER2 negative, (b) HER2 positive regardless of hormonal status, and (c) TNBC (ER, PR, and HER2 negative) [30] . Clinical and pathologic staging were determined based on the American Joint Committee on Cancer (AJCC) TNM Staging Manual, 7th edition. Pathologic complete response (pCR) was defined as no residual invasive disease in the breast or lymph nodes on surgical pathology specimens (ypT0/Tis ypN0).
All women received A-based, T-based, or A/T-based NAC and were dosed based on BSA without adjustments made based on obesity status. Women were considered to have received radiation therapy (XRT) if they received any type of whole breast/chest wall radiation with or without nodal radiation. Hormonal therapy was defined as treatment with tamoxifen only or any aromatase inhibitor (AI) and was categorized as tamoxifen only or any AI use, as some women received tamoxifen and then an AI (classified as AI use). Of the 15 women who were HR? but did not receive hormonal therapy, four deferred due to disease progression, one deferred due to pregnancy, four refused, one was lost to follow-up before initiation, five had missing data, and one woman received fulvestrant. Surgery type was stratified into lumpectomy or mastectomy with or without lymph node dissection.
Statistical analysis
Chi-square and t tests were used to compare relevant clinical and pathologic variables according to obesity status at diagnosis. EFS was based on the STEEP criteria [31] , and events were defined as any local/regional or distant metastasis, contralateral invasive breast cancer (excluding in situ disease), any secondary, non-breast, invasive cancer, and/or death by any cause. EFS and OS were calculated in months from date of diagnosis to date of first event or death (for OS) or last follow-up in those without events. KaplanMeier survival analysis and the log-rank statistic were used to estimate survival differences between groups based on clinically relevant variables. Cox proportional hazard models were used to estimate the hazard ratio for the association between obesity and EFS and OS, and to evaluate the potential interaction between obesity and other relevant covariates. Given literature suggesting differences in the association between obesity and survival among various tumor subtypes and race/ethnicity groups, stratified analyses were also performed using the a priori determined variable of subtype (HR?/HER2-, HER2?, and TNBC) and race/ethnicity (Non-Hispanic White, Non-Hispanic Black, and Hispanic). All analyses were performed using SAS 9.4 and STATA 12.0 with significance defined as a two-sided p value of less than or equal to 0.05.
Results
Demographics
BMI at diagnosis ranged from 17.6 to 50.9, with a mean of 28.8 [standard deviation (SD) 6.1]. Of the 273 women, 102 (37%) were classified as obese (BMI C 30). BMI was measured on average 2.7 months after diagnosis (SD 10.7 months) with a median time of 21 days after diagnosis (range 0-120 months), with 8 women having BMI values from over a year after diagnosis. On average, BMI changed a mean of -0.11 units (SD 3.3 units) with a median change of 0.05 units (range -10.6 to 9.3 units) over an average time period of 30.2 months (SD 22.1 months). Rates of obesity varied significantly among the different race/ethnicity groups (p \ 0.01): Non-Hispanic White (n = 91) 29% obese, Non-Hispanic Black (n = 66) 47% obese, Hispanic (n = 95) 44% obese, and Asian/Other (n = 16) 13% obese. There was a higher prevalence of diabetes (30% vs. 13%) in obese compared with non-obese women, p \ 0.01. All women received A-based, T-based, or A/Tbased NAC, and dosages were not reduced for the 10 women with BSA C 2.2 or the 14 women with BMI C 40, and there were no differences in type of surgery (lumpectomy vs. mastectomy) or XRT as compared to women with normal weight (BMI 18.5 to \ 25) and BSA \ 2.2, p [ 0.05. Otherwise, there were no differences in age, clinical size, clinical stage, grade, subtype (HR?/HER2-, HER2 positive regardless of hormone receptor status, and TNBC), surgery type (lumpectomy vs. mastectomy), hormonal therapies, trastuzumab use, or radiation therapy in obese as compared with non-obese women, p [ 0.05 (Table 1) .
Overall survival analysis
Median follow-up was 32.6 months (range 5.7-137.8 months). There were a total of 60 events with 57 being recurrence or progression of invasive breast cancer (6 local only, 9 local then distant, and 42 distant) and 3 being death from any cause without evidence of recurrence/progression. There were 29 (28%) events among obese women as compared to 31 (18%) in non-obese women. There were a total of 33 deaths from all causes, with 3 deaths occurring without recurrence/progression. There were 16 (16%) deaths among obese women as compared with 17 (10%) among non-obese women.
Among obese women, 29% achieved pCR as compared with 27% in non-obese women (X 2 , p = 0.75), and there were no differences in rates of pCR between obese and non-obese women when stratified by tumor subtype, p [ 0.05. On univariate analysis, obesity (BMI C 30 compared with BMI \ 30) was associated with significantly worse EFS (HR 1.71, 95% CI 1.03-2.84, p = 0.04). There was also a trend towards worse OS (HR 1.69, 95% CI 0.85-3.36, p = 0.13), Fig. 1 . Tumor subtype was also significantly associated with worse EFS (log-rank test p \ 0.01) and OS (log-rank test p = 0.05) with women with TNBC having worse and HER2? breast cancer having better survival outcomes than those with HR?/HER2-breast cancers (Supplementary eFigure 1). In women with HR?/HER2-tumors (n = 135), there was an interaction between obesity and hormonal therapy type (AI vs. tamoxifen only) with OS (interaction p = 0.03). In those receiving tamoxifen only (n = 33), obesity was associated with worse OS (HR 9.27, 95% CI 0.96-89.31, p = 0.05). In those receiving AIs (n = 89), there was no association between obesity and OS (p = 0.34), Table 2 / Fig. 2 . There was no significant interaction with EFS, although the effects are in the same direction as OS.
Although not statistically significant (p = 0.06), a higher proportion of women receiving AIs were obese as compared to those receiving tamoxifen (43% vs. 24%). Of the seven within this subtype who received no hormonal therapies, three were obese, of which two had disease Fig. 1 Kaplan-Meier Curves of Obesity with Event-free and Overall Survival Legend: Overall, obesity is associated with worse event-free and a trend towards worse overall survival progression and died, whereas four were not obese, of which one had local recurrence only. Hormonal therapy type was also significantly correlated with age (p \ 0.01), and older women (C 50 years) were more likely to be receiving an AI than younger women (\ 50 years). Analysis conducted with age (\ 50 years vs. C 50 years) instead of AI vs. tamoxifen only in HR?/HER2-women also showed significant interaction with OS (interaction p = 0.03) and trend with EFS (interaction p = 0.06), and obesity adversely influenced survival in younger but not older women (data not shown).
HER2 positive
In women with HER2? tumors regardless of hormone receptor status (n = 94), obesity was associated with a trend to worse EFS (HR 3.37, 95% CI 0. 
TNBC
In women with TNBC (n = 44), obesity was associated with worse EFS (HR 2.62, 95% CI 1.03-6.66, p = 0.04) Fig. 3 .
Role of race/ethnicity
The race/ethnicity analyses were limited to Non-Hispanic White, Non-Hispanic Black, and Hispanic given the small number of Asian/Others. There were no significant differences in survival (EFS and OS) between Non-Hispanic Whites, Non-Hispanic Blacks, and Hispanics either overall or stratified by the three tumor subtype groups, p [ 0.05 (Supplementary eFigure 3). There were no interactions between race/ethnicity and obesity with either EFS (interaction p = 0.24) or OS (interaction p = 0.45), after adjusting for tumor subtype.
Discussion
Overall, obesity was associated with worse survival, and the association was strongest in HR?/HER2-and TNBC with a trend in HER2?BC. In women with HR?/HER2-disease, there was a significant interaction between obesity and hormonal therapy class with survival. However, there were no differences in survival by race/ethnicity and no significant interaction between race/ethnicity and obesity on survival.
Our results are consistent with prior studies conducted in the neoadjuvant setting (Table 3) . Fontanella et al. found that obese and very obese women receiving NAC had shorter disease-free and overall survival compared with normal-weight women, particularly in Luminal A and TNBC [24] . Karatas et al. also found that obese women had lower rates of pCR, and shorter survival than normal- [16] . Moreover, in two trials before and after the introduction of trastuzumab therapy, obesity was associated with worse survival in women with HER2?BC [13, 15] . Interestingly, obesity was associated with worse EFS but not OS in our cohort of HER2 ? BC, suggesting that advances in therapy at the time of progression, such as pertuzumab and trastuzumab emtansine, are improving overall survival in this subtype [32, 33] . The mechanism of obesity's influence on survival is hypothesized to involve increased peripheral conversion of androgens to estrogen by aromatase-a process known as aromatization, which suggests that this association may be more pronounced in HR?tumors [34, 35] . As the negative influence of obesity may be present in all subtypes, the mechanism may also involve other non-estrogen-related pathways [34, 35] . Some have postulated that obesity and subsequent insulin resistance affect molecular signaling pathways including IGF-1 leading to a pro-carcinogenic In TNBC, obesity is associated with worse event-free survival and a trend towards worse overall survival state and dysregulation of growth [35, 36] . Obesity may also lead to a chronic inflammatory state that can affect cytokine signaling and lead to growth/proliferation of cancer [37] . Moreover, obesity may impact epigenetic markers and gene methylation, [38] and mouse models suggest that chronic obesity can lead to epigenetic reprogramming, up-regulation of inflammatory signaling, and mammary tissue growth [39] .
As reported in prior studies [20, 21] , we found no differences in survival between different race/ethnicity groups and no interactions between race/ethnicity and obesity on survival. Although there were no significant differences in tumor subtypes by race/ethnicity, there were significant differences in hormonal therapy utilization with Non-Hispanic Blacks less being likely to have hormone therapies listed in the medical record or have missing data (p = 0.03), suggesting potential differences in medical treatment or preference/adherence between the race/ethnicity groups. We found no differences in type of surgery, XRT, or trastuzumab use (p [ 0.05) between Non-Hispanic Whites, Non-Hispanic Blacks, and Hispanics.
Our finding of a significant interaction between obesity and hormonal therapy in HR?/HER2-BC is unexpected and hypothesis generating. Prior studies have investigated the efficacy of AIs vs. tamoxifen in obese vs. non-obese women in mostly postmenopausal women, and results are mixed [40] . In postmenopausal women, some studies have shown that obesity was associated with worse survival in women receiving anastrozole but not tamoxifen [10] ; however, others have shown no difference in benefit of letrozole vs. tamoxifen [41] as well as a significant benefit of exemestane over tamoxifen in obese women [40] . We found that in those receiving tamoxifen obesity predicted worse OS, but in those receiving AIs obesity did not predict worse survival. Studies show that aromatase activity is elevated in the mammary tissue of obese mice [42] , and the inhibition of peripheral conversion of fat to estrogen by aromatase may be particularly critical in obese women. In vivo studies have shown that AI levels are not reduced in obese women [43] and that, compared to non-obese women, estrogen levels are not elevated in obese women receiving AIs [44, 45] , but are elevated in obese women not receiving AIs [44] . AIs may block a significant pathway linking obesity and poor survival, potentially conferring a protective effect as compared with tamoxifen in obese women. Interestingly, we found that hormonal therapy was also significantly correlated with age, defined as a categorical variable with a cutoff of age 50, which may be a surrogate for menopausal status, and we observed a similar interaction between obesity and age with survival. This further suggests that menopausal status and the hormonal milieu, as influenced by anti-estrogen therapies, may influence the role of obesity on survival in this estrogen-sensitive BC population. A recent meta-analysis found that although obesity is associated with worse survival overall, there may be a suggestion of larger effect size in premenopausal versus postmenopausal women [5] . The various mechanisms relating obesity to worse survival may vary by menopausal status and hormonal therapies and differentially influence survival in HR?BC as compared with other subtypes. Unfortunately, in our study, we have not comprehensively and reliably collected data on menopausal status and instead use age (C 50) as a surrogate. However, prior studies have shown that, although definitions for menopause can vary in the literature, this only translates into slight differences in menopausal status-specific breast cancer rates [46] . Strengths of our study include modern NAC regimens, rigorous data collection techniques, a diverse population that is a majority non-White, and assessment of interactions with multiple variables including tumor subtype, race/ethnicity, and hormonal therapies. We are also the first to identify an interaction between obesity, hormonal therapy class, and tumor subtype on survival. Limitations include a relatively small sample size, an incomplete assessment of menopausal status, hormonal therapy utilization, and the retrospective nature of our study owing to potential for residual confounding.
Future studies should clarify the interaction between obesity and hormonal therapy classes, particularly different types of AIs as well as duration of therapy, in HR? disease and explore the role of menopausal status. Additionally, BMI may not capture central adiposity [35] , and future studies should also examine other measures of obesity, as studies suggest that waist circumference and waist-to-hip ratio may be independent predictors of all-cause mortality [47] , particularly in Black patients [48] .
Conclusion
In women receiving NAC for invasive BC, baseline obesity is associated with worse outcomes, particularly in those with HR ?/HER2-disease receiving tamoxifen compared with AIs and in those with TNBC. Clinically, screening for and treating obesity may be important in assessing prognosis and improving survival.
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